Programmed death-ligand 1 (PD-L1) is an immune modulator that promotes immunosuppression by binding to programmed death-1 of T-lymphocytes. Although tumor cell PD-L1 expression has been shown to be associated with the clinical response to anti-PD-L1 antibodies, its concise regulatory mechanisms remain elusive. In this study, we evaluated the associations of tumor PD-L1 expression and immune cell infiltrating patterns in 146 cases of early lung adenocarcinoma (AC) to investigate the possible extrinsic regulation of tumor PD-L1 by immune cells. Using immunohistochemistry, cell surface PD-L1 expression in tumor cells was observed in 18.5% of stage 0-IA lung AC patients. Tumor PD-L1 positivity was significantly associated with stromal invasion, which was accompanied by increased tumor-associated macrophages (TAM), CD8 + cytotoxic T cells and FoxP3 + regulatory T cells. Among these immune cells, TAM and CD8 + T cells significantly accumulated in PD-L1-positive carcinoma cell areas, which showed a tumor cell nest-infiltrating pattern. Although CD8 + T cells are known to induce tumor PD-L1 expression via interferon-ɣ production, the increased TAM within tumors were also associated with tumor cell PD-L1 positivity, independently of CD8 + T cell infiltration. Our in vitro experiments revealed that PD-L1 expression in lung cancer cell lines was significantly upregulated by co-culture with M2-differentiated macrophages; expression of PD-L1 was reduced to baseline levels following treatment with a transforming growth factor-β inhibitor. These results demonstrated that tumor-infiltrating TAM are extrinsic regulators of tumor PD-L1 expression, indicating that combination therapy targeting both tumor PD-L1 and stromal TAM might be a possible strategy for effective treatment of lung cancer.
| INTRODUC TI ON
Lung cancer, particularly non-small cell lung cancer (NSCLC), is the leading cause of cancer death worldwide, accounting for more than 1.7 million deaths every year. 1 During the past decade, developments in molecular-targeted therapies have led to major breakthroughs in the understanding, diagnosis and management of NSCLC, and treatment for advanced NSCLC is becoming increasingly personalized. Numerous molecular mutations and fusions in NSCLC patients have been discovered, including epidermal growth factor receptor (EGFR), BRAF, anaplastic lymphoma kinase (ALK) and ROS1. In addition to these therapeutic strategies, immunotherapy is emerging as a major modality in NSCLC treatment, and development of immune checkpoint inhibitors has recently shown efficacy in prolonging survival of NSCLC patients. 2 Immune checkpoint pathways play a critical role in suppressing the anti-tumor T cell-mediated immune response in the tumor microenvironment. 3, 4 Programmed death-ligand 1 (PD-L1), also known as B7-H1 or CD274, a type I transmembrane protein, is a major immune checkpoint molecule and is expressed on the surfaces of various carcinoma cells such as lung, colon, melanoma and leukemic cells. 5, 6 PD-L1 inhibits activation, expansion and acquisition of effector functions of activated cytotoxic CD8 + T cells through its interaction with programmed death-1 (PD-1; also known as PDCD1) of T cells, leading to immune escape.
Therapeutic antibodies targeting the PD-L1/PD-1 axis have been developed for clinical application, and have shown remarkable clinical responses in a variety of advanced cancers. 7 Importantly, tumor PD-L1 expression has been shown to be associated with the clinical response to anti-PD-1/PD-L1 antibodies, and its immunohistochemical detection has been established as a biomarker for the selection of NSCLC patients for anti-PD1/PD-L1 immunotherapy. To predict the efficacy and to optimize anti-PD-L1/PD-1 therapies, alone or in combination, it has become increasingly important to understand the mechanisms regulating tumor PD-L1 expression.
Tumor PD-L1 expression is known to be triggered by extrinsic as well as intrinsic factors such as gene aberrations and oncogenic drivers. Previous studies have reported that tumor-infiltrating lymphocytes upregulate PD-L1 expression on primary or metastatic tumor cells through release of interferon (INF)-ɣ in an adaptive immune-resistance fashion, suggesting that altered tumor stroma is a crucial extrinsic regulator of tumor PD-L1 expression. However, despite the diversity of stromal immune cells, information regarding the association between tumor PD-L1 expression and immune cell infiltration patterns is still limited. In this study, we analyzed the relationship between tumor PD-L1 expression and infiltrating immune cell patterns in early lung adenocarcinoma (AC) patients, and further investigated the possible extrinsic regulation of tumor PD-L1 by tumor-associated macrophages (TAM).
| MATERIAL S AND ME THODS

| Patients
On the basis of the availability of tumor PD-L1 expression status and clinicopathological data, we enrolled a series of 146 Japanese patients with Stage 0-IA lung AC surgically resected between 2010 and 2014 at Keio University Hospital, Tokyo, Japan. All patients were staged according to the 8th edition of the TNM Classification for lung cancer. 8 
| Immunohistochemistry and staining assessment
Paraffin sections were subjected to immunohistochemistry for rabbit anti-PD-L1 (1:200; E1L3N; Cell Signaling Technology), They were followed by reactions with ImmPRESS polymer HRP-conjugated anti-rabbit or anti-mouse antibodies (Vector Laboratories). Color was developed with 3, 3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich). After immunohistochemistry, the sections were counterstained with hematoxylin. For assessment of tumor cell PD-L1 expression, the percentages of tumor cells with membranous PD-L1 positive staining were recorded. A score of 5% or more was categorized as "PD-L1-positive" and a score of <5% as "PD-L1-negative" based on recent studies of tumor PD-L1 expression. [10] [11] [12] [13] For assessment of inflammatory cell infiltration in the tumor, numbers of CD3 − , CD8 − , FoxP3 − , CD68 − , CD163 − or CD204-immunostained cells were counted by observing five different fields which include both cancer cell nests and stromal areas at ×200 magnification without knowledge of the samples examined. In contrast, the severity of infiltration of immune cells into cancer cell nests but not tumor stromal areas was evaluated using a "tumor-infiltrating immune cell score," which was modified from "tumor-infiltrating lymphocytes score" originally defined in the previous literature. 14 Briefly, we evaluated CD163 + or CD204 + TAM, CD8 + T cells or FoxP3 + T cells on top of cancer cell nests as 0 (absent), 1+ (mild), 2+ (moderate) or 3+ (marked) by using CD163 − , CD204 − , CD8 − or FoxP3-stained sections, respectively. For the heterogenous study, we investigated PD-L1 + cases (27 cases), and assessment of inflammatory cell densities and tumor-infiltrating immune cell score in PD-L1 + and PD-L1 − areas was performed by observing five different fields at ×200 magnification in each area.
| Macrophage culture
As previously described, 15 human peripheral blood mononuclear cells (PBMC) were isolated from transfusion blood provided by the Japanese Red Cross Society and cultured for 8 days in Iscove's modified Dulbecco's medium (Thermo Fisher Scientific) containing 10% (v/v) human AB serum (Cosmo Bio) and M-CSF (50 ng/mL) at a density of 3.5 × 10 6 cells/1.5 mL/well in 12-well cluster plates (Corning). They were then polarized to M2a macrophages through addition of IL-4 (20 ng/ mL) and IL-13 (25 ng/mL) or to M2c macrophages through addition of IL-10 (25 ng/mL) and dexamethasone (7 nmol/L), or left untreated for the duration of the culture (M0), following previous studies. 16 M2a or M2c macrophages on the Lab-Tek chamber slides (Nalge Nunc International) for 2 days. Co-cultured cells were fixed with methanol/ acetone/formaldehyde, 18 and double-immunostained with rabbit anti-PD-L1 antibody, followed by reactions with anti-rabbit IgG conjugated to Alexa-Flour 594 (Invitrogen). The cells were counterstained with DAPI (Invitrogen) and mounted in Vectashield (Vector). As for controls, cells were reacted with rabbit non-immune IgG (data not shown). These samples were observed by confocal microscope (LSM 510; Zeiss).
| Direct co
| Immunoblotting
Cultured cells were homogenized in lysis buffer containing 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 10 mmol/L CaCl 2 , 1% NP-40, complete proteinase inhibitors (Roche Diagnostics) and
homogenate supernatants were used for sodium dodecyl sulfatepolyacrylamide gel electrophoresis. 18 Proteins were transferred to polyvinylidene difluoride membranes, and the membranes were incubated with rabbit anti-PD-L1 antibody (E1L3N; Cell Signaling Technology) or rabbit anti-β-actin antibody conjugated with HRP (13E5; Cell Signaling Technology). For anti-PD-L1 antibody, the membranes were subsequently incubated with secondary antibodies. They were further visualized by chemiluminescence.
| Stimulation of cancer cells with M2 macrophage-producing cytokines
Serum-starved human NSCLC cell lines A549 and H1975 were treated with human transforming growth factor (TGF)-β1 (2 ng/mL; R&D Systems) or human IL-10 (10 ng/mL; R&D Systems), human tumor necrosis factor (TNF)-α (10 ng/mL; BioLegend), human IL-6 (10 ng/mL; BioLegend), human IL-1α (10 ng/mL; R&D Systems) or human IL-1β (10 ng/mL; R&D Systems) in serum-free RPMI1640 containing 0.2% lactalbumin hydrolysate for 12 or 24 hours. Cells were also treated with vehicle alone as controls. The expression of PD-L1 under treatment with these cytokines was analyzed by quantitative PCR. Protocols for all other procedures are provided in Data S1. (18.5%) by immunohistochemistry ( Figure 1A ). PD-L1 was expressed on both cancer and immune cells, and these cells could be distinguished by morphological features. In PD-L1-positive tumors, PD-L1 expression in tumor cells showed a heterogeneous staining pattern. For example, 5%-24%, 25%-49% and more than 50% of tumor cells were positive for PD-L1 in 16, 6 and 5 of 27 cases, respectively ( Figure 1B) . Analyses of the correlations between tumor PD-L1 status and clinicopathological and molecular characteristics showed that tumor PD-L1 positivity was significantly associated with a higher rate of smoking history (P < 0.001), stromal invasion (P < 0.001), tumor size (P < 0.001), EGFR wild-type status (P = 0.003) and vascular invasion (P = 0.039; Table 1 ).
| Statistical analysis
| RE SULTS
| Tumor programmed death-ligand 1 expression is associated with stromal invasion accompanied by increased immune cells in early lung adenocarcinoma
Among them, stromal invasion is known to affect stromal immune responses in the tumor microenvironment. 19 Immunohistochemical analyses consistently revealed that invasive AC contained significantly increased CD68 + , CD163 + or CD204 + macrophages, CD8 + cytotoxic T cells, and FoxP3 + regulatory T cells compared to noninvasive AC in situ ( Figure 1C ).
| Tumor-associated macrophages and CD8 + T cells accumulated in programmed death-ligand 1-positive carcinoma cell nests, and showed an infiltrating pattern
We 
| Tumor programmed death-ligand 1 expression was upregulated by co-culture with peripheral blood mononuclear cell-derived M2-differentiated macrophages
The majority of TAM show immunosuppressive M2a or M2c phenotypes. 21 Using qPCR, Figure 4A shows that PBMC-derived M2a- Figure 4F ). Figure 5 ). Increased PD-L1 protein was also detected in A549 and H1975 cells by treatment with TGF-β1 by immunoblotting ( Figure 6A) , and flow cytometry analysis confirmed a tendency for higher PD-L1 expression in TGF-β1-treated A549 and H1975 cells compared to controls ( Figure 6B) . Importantly, the TGF-β concentrations in the conditioned media from A549 cells co-cultured with PBMC-derived M2a or M2c macrophages were significantly elevated compared to those from A549 cells alone ( Figure 6C ). The enhanced expression of PD-L1 in A549 cells by co-culture with M2a or M2c macrophages was reduced to basal levels following treatment with the TGF-β inhibitor SB431542
| Transforming growth factor-β1 is involved in the tumor-associated macrophage-mediated tumor programmed death-ligand 1 expression
( Figure 6D ), suggesting that TGF-β was involved in TAM-mediated tumor PD-L1 induction.
| D ISCUSS I ON
Immunotherapies targeting the PD-1/PD-L1 pathway have been a recent breakthrough in the treatment of human malignant diseases, including NSCLC. Although PD-L1 expression has been shown to be associated with the clinical response to anti-PD-L1 antibodies, its concise regulatory mechanisms remain elusive. In this study, we showed that tumor PD-L1 positivity was associated with stromal invasion accompanied by increased immune cell infiltration in early lung AC.
Among these immune cells, TAM infiltration was an additional factor related to tumor PD-L1 expression, independent of CD8 + T cell infiltration. Our in vitro experiments showed that M2-differentiated macrophages facilitated tumor PD-L1 expression through TGF-β. Together, these results suggested that TAM were extrinsic regulators of tumor PD-L1 expression and could serve as potential therapeutic targets.
In the present study, tumor PD-L1 expression was detected 22C3 (pembrolizumab). 22 The antibody used here (E1L3N) is not related to drugs, but its specificity and sensitivity were validated in a previous report by Inamura et al 13 and we defined a score of 5% or more as "PD-L1-positive," based on previous studies. 13, 23 Inamura et al showed that tumor PD-L1 positivity was associated with less tumor differentiation and the EGFR wild-type status, 13 similar to our findings, and we further identified "stromal invasion" as an additional factor related to tumor PD-L1 positivity in early lung AC. Stromal invasion is known to affect stromal remodeling and immune responses, 19 and our study showed that tumor PD-L1 expression was closely associated with increased numbers of tumor-infiltrating TAM. TAM are known to show an immunosuppressive phenotype by attracting other immunosuppressive cells such as regulatory T cells, myeloid-derived suppressor cells and type 2 helper T cells. 21, 24, 25 Recently, TAM infiltration has been reported to be associated with the upregulation of PD-L1 Inhibition studies using a TGF-β inhibitor showed that TGF-β was dispensable for upregulation of PD-L1 in tumor cells by co-culture with M2 macrophages. Notably, recent studies have reported that TGF-β restrains the anti-tumor immune response by blocking T cells from infiltrating the tumor. 31, 32 TGF-β has also been reported to promote regulatory T cell development, 33 which may explain the enhanced FoxP3 + T cell infiltration in TAM-rich PD-L1 + tumor areas in our study. TAM-derived TGF-β is, therefore, thought to be a key factor in the creation of the immunosuppressive tumor microenvironment ( Figure 6E) .
Consistent with previous studies, we have shown that macrophages significantly express PD-L1 during TAM-like M2 differentiation ( Figure 4A ). Recent studies using various mouse tumor models have In this study, we showed that infiltration of TAM is involved in tumor PD-L1 induction through production of cytokines such as TGF-β in early lung adenocarcinoma. Upregulated PD-L1 in macrophages during M2 differentiation may also directly contribute to immune suppression. In addition, TGF-β is known to promote FoxP3 + regulatory T cell development and inhibit CD8 + T cell functions, suggesting that TAM infiltration within the tumor is a key factor for creation of the immunosuppressive tumor microenvironment. * P < 0.05, * * P < 0.01 and is considered a key factor indicating suitability for checkpoint blockade therapy. 42, 43 PD-L1 overexpression in tumor cells is also related to oncogenic mutations in phosphatase and tensin homologues 44 and nucleophosmin-ALK. 45 In this study, these genetic/ epigenetic alterations in tumor tissues were not evaluated, except for EGFR mutations. Second, based on our data, we speculate that 
